*This is a blog about glaucoma and it is not medical advice. See your ophthalmologist for specific advice."
In the evolving landscape of glaucoma management, the Laser in Glaucoma and Ocular Hypertension (LiGHT) trial (often stylized "LiGHT" or "LIGHT") stands out as a landmark study. It provides high-quality evidence that selective laser trabeculoplasty (SLT) can be a safe, effective, and cost-efficient first-line alternative to eye drops (topical therapy) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT).
Below is a clear, reader-friendly summary of the benefits, key findings, and clinical implications, including the important observation that patients randomized to medical therapy had higher rates of invasive glaucoma surgery.
Key Benefits of SLT (as demonstrated in LiGHT) — and Why It Is Recommended
SLT has long been used as an adjunctive therapy in glaucoma. What LiGHT did was to test it as a primary therapy. Some of the major benefits highlighted by the trial include:
Medication-free pressure control (or reduction of medication burden). One of the most compelling advantages is that many patients in the SLT-first arm avoided or delayed the need for topical glaucoma medications. This is attractive given issues with adherence, side effects, cost, and tolerability of drops.
Lower need for invasive glaucoma surgery. Over the long term, eyes in the SLT-first arm required fewer incisional glaucoma surgeries (such as trabeculectomy or other filtering surgery) compared to the medical therapy arm.
Better long-term disease control and lower progression risk. Eyes started on SLT demonstrated less glaucoma progression (optic nerve or visual field progression) than those started on drops. This suggests an impact not only on pressure but on disease trajectory.
Favorable safety profile. SLT carries a relatively low risk of severe complications. The LiGHT trial reported no serious laser-related adverse events over the follow-up period.
Cost-effectiveness. Because patients on SLT often avoided or reduced medication use, and had fewer surgeries, the overall cost of care was lower in the SLT-first arm. LiGHT showed SLT-first was cost-saving over 3 to 6 years in the UK setting.
Quality-of-life considerations and treatment burden. By reducing the need for daily drops, SLT reduces the burden of adherence, side effects (e.g. ocular surface irritation, systemic absorption), and challenges with instilling multiple medications. This can translate into better patient satisfaction and fewer drop-related complications.
Because of these advantages, many glaucoma specialists and guideline committees now consider SLT a valid option for initial therapy (i.e. before or instead of beginning drops) in selected patients.
LiGHT Study: Design and Key Findings
Study Design Overview
The LiGHT trial was a multicenter, randomized, controlled, observer-masked trial comparing primary SLT vs primary medical therapy (eye drops) in treatment-naïve patients with open-angle glaucoma or ocular hypertension (OAG/OHT). Patients were assigned to either SLT-first (laser arm) or medical therapy-first (drops arm). Treatment escalation and crossover protocols were built in to maintain target intraocular pressure (IOP) goals. Follow-up extended through 6 years for many participants, with extension data reported.
Major Results & Metrics
Glaucoma progression occurred in 19.6% of the SLT arm versus 26.8% of the drops-only arm (P = 0.006).
Trabeculectomy (or incisional glaucoma surgery) was needed in 13 eyes in the SLT arm compared to 32 eyes in the drops-only arm — significantly fewer surgeries in the SLT arm (P < 0.001).
Cataract surgery was required in 57 eyes in one comparison arm versus 95 eyes in the other, statistically higher in the drops arm (P = 0.03).
No serious laser-related adverse events were reported over 6 years — the trial found no sight-threatening laser complications.
Quality-of-life (generic EQ-5D) at 3 years showed no significant difference versus the drops arm. The extension beyond 3 years reinforced the initial benefits: the majority in the SLT-first arm remained controlled without medications, and some medically treated eyes that switched to SLT showed substantial reduction in medication load.
Secondary analyses have also explored applying SLT after a period of medical therapy, showing it can reduce medication burden and delay surgery, though it may not completely eliminate the need for surgery in certain cases.
Why the Higher Rates of Invasive Surgery Matter
One of the most compelling arguments in favor of SLT-first comes from the difference in rates of invasive glaucoma surgery between the groups. The drops-first arm had 32 eyes requiring trabeculectomy or other incisional glaucoma surgery over the study period, compared to only 13 eyes in the SLT arm. This suggests that a medical-first approach may predispose patients to a higher cumulative burden of requiring incisional surgical interventions, which carry greater risk, recovery time, and cost.
From a patient perspective, avoiding or delaying trabeculectomy, tube shunts, or other filtering procedures is desirable because of surgical risk (e.g. hypotony, bleb complications, infection, scarring), longer recovery, and impact on vision and quality of life.
Thus, one strong takeaway is that patients randomized to drops-first had higher invasive surgery rates — a finding that underscores the potential protective benefit of early SLT in preserving options and reducing surgical burden.
Clinical Implications & Recommendations
Offer SLT as a first-line option in newly diagnosed OAG/OHT. In patients with mild to moderate disease and open angles, discussion of SLT-first is reasonable. It should not be seen only as a fallback after medications fail.
Individualize based on risk, anatomy, severity, and patient preference. SLT is not suitable for all glaucoma types (e.g. narrow angles, angle-closure, neovascular glaucoma) or advanced disease in some cases. But for many, SLT offers a favorable risk-benefit tradeoff.
Monitor and plan for retreatment or escalation. SLT is not invariably permanent. Some patients will require repeat SLT, rescue medications, or even surgery down the line. The optimal interval and criteria for retreatment remain active areas of investigation.
Educate patients about long-term strategy, not just initial pressure lowering. Emphasize that the goal is to reduce progression, preserve vision, and minimize invasiveness and side effects.
In health systems and policy, consider cost and resource implications. The economic analyses from LiGHT show SLT-first is cost-saving in many settings, chiefly by reducing medication usage, fewer surgeries, and fewer visits.
Continue gathering long-term, real-world evidence. As more centers adopt a laser-first paradigm, it will be important to monitor outcomes (duration of effect, repeatability, patient selection, long-term safety) in diverse populations.
Limitations, Caveats & Continuing Questions
No trial is perfect. LiGHT was conducted in the UK and included mostly White patients, so generalizability across ethnicities and healthcare settings needs confirmation. How often SLT should be repeated, and at what energy, remains unsettled — some patients may lose responsiveness over time. The trial enrolled patients with mild-to-moderate disease, so whether SLT-first is safe and effective in more advanced glaucoma is less proven. In clinical practice, patients may differ in anatomy, comorbidities, angle visibility, and response, which may influence outcomes. Although no serious adverse events were reported in LiGHT, the long-term cumulative safety of repeat SLT over decades needs continued observation.
Conclusion
The LiGHT study is a high-impact, practice-shifting trial that demonstrates the benefits of selective laser trabeculoplasty (SLT) as a first-line therapy in open-angle glaucoma and ocular hypertension. The advantages are compelling: many patients maintain medication-free IOP control, fewer incisional glaucoma surgeries, lower rates of progression, favorable safety, and cost-effectiveness. The counterpoint — that patients managed initially with medications had higher rates of invasive surgery — bolsters the case for considering SLT early on.
For patients and clinicians navigating glaucoma therapy choices, LiGHT provides strong, evidence-based justification to offer SLT earlier, rather than relegating it to a last resort.
References
- Gazzard G, Konstantakopoulou E, Garway-Heath D, et al. Selective laser trabeculoplasty versus eye drops for the first-line treatment of ocular hypertension and glaucoma (LiGHT): a multicentre randomized controlled trial. Lancet. 2019;393:1505-1516. Gazzard G. Laser in Glaucoma and Ocular Hypertension (LiGHT) Trial. Ophthalmology (AAO Journal). "Laser in Glaucoma and Ocular Hypertension (LiGHT) Trial" 6-year results. Ophthalmology. Konstantakopoulou E, et al. Selective Laser Trabeculoplasty After Medical Treatment: extension of LiGHT trial. JAMA Ophthalmology. </content>